Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|5|664-674

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.5, 2014-03, pp. : 664-674

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Experience in Integrating ALK Testing and Crizotinib into the Routine Treatment of Patients with Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-04 ,pp. : 342-347

Karger

Access to resources Recommend Favorite

ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

By  

CANCER, Vol. 120, Iss. 16, 2014-08 ,pp. : 2392-2402

John Wiley & Sons Inc

Access to resources Recommend Favorite

Detection of Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Non-Small Cell Lung Cancer and Related Issues in ALK Inhibitor Therapy: A Literature Review

By Yi Eunhee S.  

Molecular Diagnosis & Therapy, Vol. 16, Iss. 3, 2012-06 ,pp. : 143-150

Adis International

Access to resources Recommend Favorite

EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 83, Iss. 5, 2012-09 ,pp. : 248-256

Karger

Access to resources Recommend Favorite

Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 509-513

Karger

Access to resources Recommend Favorite